39748Tirzepatide sodium salt 5 mg and 6 more items

Cayman Chemical Company Inc has been awarded a contract by Virginia Commonwealth University with an award date of September 21, 2026, for a cumulative contract value of $957. The contract is executed in the Commonwealth of Virginia and calls for delivery of pharmaceutical compounds to VCU Procurement. The prime contractor will supply seven distinct chemical compounds, each in single-unit quantities: Liraglutide 5 mg ($140), Tirzepatide sodium salt 5 mg ($105), Retatrutide sodium salt 1 mg ($63), Semaglutide trifluoroacetate salt 1 mg ($79), Lixisenatide acetate 5 mg ($86), Bamadutide 1 mg ($87), and TC4 1 mg ($397).

The contract encompasses the procurement of specialized pharmaceutical research chemicals, with unit prices ranging from $63 to $397 per item. These compounds appear to be glucagon-like peptide receptor agonists and related pharmaceutical intermediates for research and development purposes at Virginia Commonwealth University. The relatively modest contract value and single-unit quantities for each line item suggest this may represent a research supply requirement rather than a bulk pharmaceutical procurement. No specific period of performance dates are provided in the contract documentation beyond the award date of September 21, 2026.